Bosentan
Hepatopulmonary Syndrome
Medical University of ViennaSmall moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hepatopulmonary Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pentoxifylline University of Alabama at Birmingham | Phase 1 | CC |
Same molecule, other indications
Bosentan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →